medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 3

<< Back Next >>

Gac Med Mex 2017; 153 (3)

Diagnóstico tardío de psoriasis: motivos y consecuencias

Quiroz-Vergara JC, Morales-Sánchez MA, Castillo-Rojas G, López-Vidal Y, Peralta-Pedrero ML, Jurado-Santa Cruz F, Ponce de León-Rosales S

Language: Spanish
References: 35
Page: 335-343
PDF size: 136.50 Kb.


ABSTRACT

Background: Psoriasis is an autoimmune skin disease that may be associated with articular manifestations, and the most common clinical presentation is the variety “in plaques”. In Mexico, in the Centro Dermatológico Pascua, it is the eighth leading cause of consultation. The aim of this study was to determine the diagnostic process of patients in a reference center for diseases of the skin. Methods: Performing an analytical cross-sectional study that included 100 patients where the diagnostic process was questioned, clinimetric scales were applied and evaluated anthropometric. Results: It was found that 70% of patients had taken over a month to get medical care (median: 3 months; IQR: 11 months), having consulted in 61% to a general physician as a doctor of first contact and 89% being diagnosed by a dermatologist. Eighty-eight percent of the patients were overweight or obese. We found as a factor of delay, a partnership with the variable of having an Institutional Medical Service (p = 0.019; U = 695.5). Conclusion: it is necessary to design a system to shorten the diagnostic process, not only in psoriasis, in addition to emphasizing dermatological education.


REFERENCES

  1. Jiménez Gómez N, Ballester Martínez MA, Pérez Gala S, Gárate Ayastuy MT. Psoriasis. Medicine. 2014;11:2764-73.

  2. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61:1373-8.

  3. Van de Kerkhof PCM, Nestlé FO. Psoriasis. En: Bolognia J, Jorizzo J, Schaffer J, editores. Dermatology. 3rd ed. United Kingdom: Saunders; 2012. p. 135-56.

  4. Boehncke WH, Schön MPE. Psoriasis. Lancet. 2015;386:983-94.

  5. Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-85.

  6. Farber EM, Nall L. Epidemiology: natural history and genetics. En: Roenigk Jr HH, Maibach HI, editores. Psoriasis. New York: Dekker; 1998. p. 107-57.

  7. Registros del diagnóstico situacional del sistema de informática y estadística del Centro Dermatológico “Dr Ladislao de la Pascua”, reportados al Sistema Único Automatizado para la Vigilancia Epidemiológica (SUAVE) y Sistema Único de Información para la Vigilancia Epidemiológica (SUIVE). En línea: https://www.sinave.gob.mx/SUAVE/Inicio_sesion.aspx (Fecha de consulta: 12/01/2016

  8. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatologic Clinics. 2015;33:13-23.

  9. Davidovic BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. Investigative Dermatol. 2010;130:1785-96.

  10. Colombo D, Cassano N, Bellia G, et al. Gender medicine and psoriasis. World J Dermatol. 2014;3:36-44.

  11. Daudéna E, Herrerab E, Puigc L, et al. Impacto en la calidad de vida relacionada con la salud de pacientes con psoriasis activa y estable. Estudio PSO-LIFE. Actas Dermosifiliogr. 2013;104:685-93.

  12. Ferrándiz Forastera C, García-Díez A, Lizán Tudela L, et al. Impacto de la psoriasis en la calidad de vida relacionada con la salud. Med Clin (Barc). 2007;128:325-9.

  13. Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33:41-55.

  14. Jurado Santa Cruz F, Peralta CG, Morales Sánchez MA, et al. Psoriasis y síndrome metabólico. Revista del Centro Dermatológico Pascua. 2013;22:50-5.

  15. Blum A, Brand CU, Ellwanger U, et al. Awareness and early detection of cutaneous melanoma: an analysis of factors related to delay in treatment. Br J Dermatol. 1999;141:783-7.

  16. Hajdarevic S, Hörnsten A, Sundbom E, et al. Health-care delay in malignant melanoma: various pathways to diagnosis and treatment. Dermatol Res Pract. 2014;2014:294287.

  17. Haroon M, Gallagher P, Fitz Gerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045-50.

  18. Cardiff University. Dermatology Life Quality Index. April 1992. (Consultado el 4/12/2015.) Disponible en: http://www.cardiff.ac.uk/dermatology/ quality-of-life/dermatology-quality-of-life-index-dlqi/

  19. Husni ME, Meyer KH, Cohen DS, et al. The PASE questionnaire: pilot- testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57:581-7.

  20. Rich PH, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206-12.

  21. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol. 2004;51:563-9.

  22. Cardiff University. Psoriasis Disability Index. 1985. (Consultado el 4/12/2015.) Disponible en: http://www.cardiff.ac.uk/dermatology/quality- of-life/psoriasis-disability-index-pdi/

  23. PASI Training. (Consultado el 4/12/2015.) Disponible en: http://www. pasitraining.com

  24. IMSS. Calcula tu IMC. (Consultado el 4/12/2015.) Disponible en: http:// www.imss.gob.mx/salud-en-linea/calculaimc

  25. Secretaría de Salud. Tratamiento farmacológico para pacientes adultos con psoriasis en placas. Secretaria de Salud, 2013. México. (Consultado el 4/12/2015.) Disponible en: www.cenetec.salud.gob.mx/descargas/gpc/ CatalogoMaestro/IMSS-696-FARMACOLOGICO_PSORIASIS_EN_PLACAS/ IMSS-696-13-GER-TX_FX_PSORIASIS_EN_PLACAS.pdf

  26. Cervantes-González AJ, Morales-Sánchez MA, Jurado-Santa Cruz F. Epidemiology of dermatologic disorders at a referral skin center in México City. J Am Acad Dermatol. 2015;5(Supl 1):AB 97.

  27. Swetter SM, Soon S, Harrington CR, et al. Effect of health care delivery models on melanoma thickness and stage in a university-based referral center. Arch Dermatol. 2007;143:30-6.

  28. Baade PD, English DR, Youl PH, et al. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Arch Dermatol. 2006;142:1422-7.

  29. Rodríguez Morales JR, De Armas Ramírez EL. Enfermedad de Bowen. Acta Médica del Centro. 2013;7(3).

  30. Sorensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74:e12.

  31. Ojeda RM, Graells J. Estudio comparativo de la habilidad en el diagnóstico clínico del cáncer cutáneo entre el médico de familia y el dermatólogo en una misma área geográfica. Actas Dermosifiliogr. 2011;102:48-52.

  32. Borges Yáñez SA, Gómez Dantés H. Uso de los servicios de salud por la población de 60 años y más en México. Salud Pública de México. 1998;40:1-10.

  33. Jacobi A, Langenbruch A, Purwins S, et al. Prevalence of obesity in patients with psoriasis: results of the National Study PsoHealth3. Dermatology. 2015;231:231-8.

  34. Fleming P, Kraft J, Gulliver WP, et al. The relationship of obesity with the severity of psoriasis: a systematic review. J Cutan Med Surg. 2015;19:450-6.

  35. Encuesta Nacional de Salud y Nutrición (ENSANUT). 2012. (Consultado el 4/12/2015.) Disponible en: http://ensanut.insp.mx/




2020     |     www.medigraphic.com